A detailed history of Guggenheim Capital LLC transactions in Repligen Corp stock. As of the latest transaction made, Guggenheim Capital LLC holds 1,686 shares of RGEN stock, worth $210,294. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,686
Previous 1,931 12.69%
Holding current value
$210,294
Previous $243,000 2.88%
% of portfolio
0.0%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$119.79 - $167.35 $29,348 - $41,000
-245 Reduced 12.69%
1,686 $250,000
Q2 2024

Aug 14, 2024

SELL
$120.0 - $182.95 $120,000 - $182,950
-1,000 Reduced 34.12%
1,931 $243,000
Q1 2024

May 14, 2024

BUY
$170.78 - $208.42 $92,562 - $112,963
542 Added 22.69%
2,931 $539,000
Q4 2023

Feb 14, 2024

SELL
$114.17 - $185.35 $247,748 - $402,209
-2,170 Reduced 47.6%
2,389 $429,000
Q3 2023

Nov 14, 2023

BUY
$138.78 - $176.51 $53,013 - $67,426
382 Added 9.15%
4,559 $724,000
Q2 2023

Aug 11, 2023

BUY
$138.42 - $180.31 $30,175 - $39,307
218 Added 5.51%
4,177 $590,000
Q1 2023

May 10, 2023

SELL
$154.26 - $198.1 $354,026 - $454,639
-2,295 Reduced 36.7%
3,959 $666,000
Q4 2022

Feb 14, 2023

BUY
$162.42 - $220.56 $289,919 - $393,699
1,785 Added 39.94%
6,254 $1.06 Million
Q3 2022

Nov 14, 2022

SELL
$160.42 - $256.21 $69,141 - $110,426
-431 Reduced 8.8%
4,469 $837,000
Q2 2022

Aug 15, 2022

SELL
$140.68 - $188.02 $56,975 - $76,148
-405 Reduced 7.63%
4,900 $796,000
Q1 2022

May 16, 2022

SELL
$161.19 - $257.96 $479,217 - $766,915
-2,973 Reduced 35.91%
5,305 $998,000
Q4 2021

Feb 14, 2022

SELL
$247.59 - $304.47 $697,708 - $857,996
-2,818 Reduced 25.4%
8,278 $2.19 Million
Q3 2021

Nov 15, 2021

BUY
$194.77 - $324.21 $14,412 - $23,991
74 Added 0.67%
11,096 $3.21 Million
Q2 2021

Aug 13, 2021

SELL
$165.87 - $220.95 $335,057 - $446,319
-2,020 Reduced 15.49%
11,022 $2.2 Million
Q1 2021

May 13, 2021

SELL
$180.37 - $226.26 $304,103 - $381,474
-1,686 Reduced 11.45%
13,042 $2.54 Million
Q4 2020

Feb 16, 2021

SELL
$148.08 - $206.57 $477,854 - $666,601
-3,227 Reduced 17.97%
14,728 $2.82 Million
Q3 2020

Nov 13, 2020

BUY
$122.51 - $158.27 $496,778 - $641,784
4,055 Added 29.17%
17,955 $2.65 Million
Q2 2020

Aug 14, 2020

BUY
$94.33 - $140.48 $51,409 - $76,561
545 Added 4.08%
13,900 $1.72 Million
Q1 2020

Jun 02, 2020

SELL
$84.96 - $109.14 $340,434 - $437,323
-4,007 Reduced 23.08%
13,355 $1.29 Million
Q4 2019

Feb 14, 2020

BUY
$73.84 - $93.08 $337,005 - $424,817
4,564 Added 35.66%
17,362 $1.61 Million
Q3 2019

Nov 14, 2019

BUY
$76.65 - $95.51 $381,640 - $475,544
4,979 Added 63.68%
12,798 $982,000
Q2 2019

Aug 14, 2019

BUY
$54.2 - $85.95 $35,121 - $55,695
648 Added 9.04%
7,819 $672,000
Q1 2019

May 15, 2019

SELL
$49.45 - $62.8 $54,197 - $68,828
-1,096 Reduced 13.26%
7,171 $424,000
Q4 2018

Feb 14, 2019

SELL
$48.26 - $68.88 $360,212 - $514,120
-7,464 Reduced 47.45%
8,267 $436,000
Q3 2018

Nov 14, 2018

BUY
$46.8 - $58.97 $103,428 - $130,323
2,210 Added 16.34%
15,731 $872,000
Q2 2018

Aug 14, 2018

SELL
$35.26 - $47.04 $1.16 Million - $1.55 Million
-33,032 Reduced 70.96%
13,521 $636,000
Q1 2018

May 15, 2018

BUY
$30.92 - $37.27 $81,474 - $98,206
2,635 Added 6.0%
46,553 $1.69 Million
Q4 2017

Feb 14, 2018

BUY
$32.53 - $38.92 $1.43 Million - $1.71 Million
43,918
43,918 $1.59 Million

Others Institutions Holding RGEN

About REPLIGEN CORP


  • Ticker RGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 55,491,200
  • Market Cap $6.92B
  • Description
  • Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....
More about RGEN
Track This Portfolio

Track Guggenheim Capital LLC Portfolio

Follow Guggenheim Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Guggenheim Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Guggenheim Capital LLC with notifications on news.